VGS Initiates U.S. Pivotal Trial to Evaluate the Use of Its VEST Technology for Bypass Surgery

TEL AVIV, Israel, April 23, 2018 /PRNewswire/ — Vascular Graft Solutions Ltd (VGS) announces on enrollment of the first 20 patients into the VEST US pivotal trial that will evaluate the safety and effectiveness of the VEST, a novel external support device for treatment of saphenous vein graft disease after coronary artery bypass grafting (CABG).

“After more than 1,000 successful implantations in Europe, we are excited to achieve this important milestone and begin our pivotal trial in the U.S.” said Eyal Orion, founder and CEO of VGS.

Link to Press Release